By contrast, the CIMBA consortium reported that SNP rs9397435 (the tag they used for rs12662670; r2 = 0.61, r2 = 0.50 and r2 = 0.85 in HapMap2 CEU, JPT and CHB samples, respectively) shows evidence of modification of risk in both BRCA1 and BRCA2 mutation carriers (who mainly develop ER− and ER+ tumours respectively) [7] whilst similarly, we find that SNP rs12662670 is associated with increased risks of both ER− and ER+ tumours. This evidence concerns the gene BRCA1 and neoplasm.